- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Patent holdings for IPC class A61K 31/505
Total number of patents in this class: 5207
10-year publication summary
|
289
|
310
|
280
|
311
|
296
|
312
|
263
|
262
|
268
|
178
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10727 |
85 |
| Bristol-myers Squibb Company | 4872 |
77 |
| Merck Sharp & Dohme LLC | 3748 |
74 |
| Boehringer Ingelheim International GmbH | 4645 |
59 |
| Rigel Pharmaceuticals, Inc. | 538 |
59 |
| Janssen Sciences Ireland Unlimited Company | 400 |
57 |
| Janssen Pharmaceutica N.V. | 3376 |
47 |
| Acetylon Pharmaceuticals, Inc. | 69 |
45 |
| Merck Sharp & Dohme Corp. | 2191 |
41 |
| Amarin Pharmaceuticals Ireland Limited | 271 |
41 |
| AstraZeneca AB | 2898 |
39 |
| Abbvie Inc. | 1799 |
38 |
| Takeda Pharmaceutical Company Limited | 2703 |
37 |
| Dana-Farber Cancer Institute, Inc. | 2574 |
32 |
| ViiV Healthcare Company | 154 |
30 |
| F. Hoffmann-La Roche AG | 7939 |
29 |
| The Regents of the University of California | 20015 |
28 |
| Merck Patent GmbH | 5814 |
26 |
| Signal Pharmaceuticals, LLC | 181 |
25 |
| FUJIFILM Corporation | 29489 |
24 |
| Other owners | 4314 |